Wells Fargo & Company MN Has $593,000 Holdings in COMPASS Pathways plc (NASDAQ:CMPS)

Wells Fargo & Company MN lessened its position in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 48.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 156,748 shares of the company's stock after selling 145,067 shares during the period. Wells Fargo & Company MN owned about 0.23% of COMPASS Pathways worth $593,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. BIT Capital GmbH bought a new position in COMPASS Pathways during the fourth quarter worth about $437,000. EntryPoint Capital LLC boosted its stake in shares of COMPASS Pathways by 55.2% during the 4th quarter. EntryPoint Capital LLC now owns 65,519 shares of the company's stock worth $248,000 after acquiring an additional 23,311 shares during the period. Simplify Asset Management Inc. acquired a new position in shares of COMPASS Pathways during the 4th quarter worth approximately $54,000. Brown University lifted its holdings in COMPASS Pathways by 194.6% during the 4th quarter. Brown University now owns 214,200 shares of the company's stock valued at $810,000 after purchasing an additional 141,500 shares during the last quarter. Finally, Essential Planning LLC. bought a new position in shares of COMPASS Pathways in the fourth quarter valued at about $70,000. 46.19% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CMPS has been the subject of several research analyst reports. Stifel Nicolaus assumed coverage on shares of COMPASS Pathways in a report on Thursday, February 27th. They set a "buy" rating and a $11.00 target price for the company. Canaccord Genuity Group decreased their target price on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating on the stock in a research report on Friday, February 28th. Royal Bank of Canada reissued an "outperform" rating and set a $18.00 price target on shares of COMPASS Pathways in a report on Wednesday, January 15th. HC Wainwright reissued a "buy" rating and issued a $45.00 target price on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of COMPASS Pathways in a research report on Friday, March 28th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, COMPASS Pathways presently has a consensus rating of "Buy" and a consensus price target of $20.20.

COMPASS Pathways Price Performance

NASDAQ:CMPS traded down $0.15 during mid-day trading on Monday, reaching $4.04. The stock had a trading volume of 747,118 shares, compared to its average volume of 798,663. The stock has a 50-day simple moving average of $3.34 and a two-hundred day simple moving average of $4.10. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways plc has a 12 month low of $2.49 and a 12 month high of $9.63. The stock has a market capitalization of $374.40 million, a PE ratio of -1.84 and a beta of 2.27.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.01). On average, equities analysts anticipate that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.